Advertisement

Topics

Nippon Boehringer Ingelheim Company Limited Company Profile

17:31 EST 23rd November 2017 | BioPortfolio

Diagnostics

Location

10-1 Yato 3-chome Kawanishi
Kobe
Hyogo
666
Japan

Contact

Phone: 81 727 93 8351
Fax: 81 727 93 8566


News Articles [632 Associated News Articles listed on BioPortfolio]

Boehringer Ingelheim Enters the Clinic with Two New Diabetes Drugs

Boehringer Ingelheim starts two new Phase I trials with drugs intended to treat type 2 diabetes and obesity discovered through a partnership with Danish biotech Zealand.  The new Phase I trials initi...

Geisinger, Boehringer Ingelheim Announce Collaboration

INDIANAPOLIS (dpa-AFX) - Geisinger and Boehringer Ingelheim, on behalf of its diabetes alliance with Eli Lilly and Company (LLY) announced a collaboration to develop a risk-prediction model for th...

Boehringer Ingelheim mit gutem Wachstum im ersten Halbjahr 2017

Ingelheim (ots) - - Querverweis: Bildmaterial wird über obs versandt und ist abrufbar unter http://www.presseportal.de/bilder - Boehringer Ingelheim zieht eine positive Bilanz nach dem ersten Halbj.....

Boehringer Ingelheim initiates phase IIa study of liver disease NASH compound

Boehringer Ingelheim and pharmaceutical company Pharmaxis announce that Boehringer Ingelheim has initiated a European and North American phase IIa trial in NASH with BI 1467335 (formerly known as PX...

Boehringer Ingelheim expands collaboration with Sarah Cannon Research Institute

Boehringer Ingelheim and Sarah Cannon Research Institute announced an expansion of their strategic partnership to bring innovative treatments to cancer patients by developing novel immuno-oncology the...

Is Boehringer Ingelheim moving away from traditional medicines in favour of biopharmaceuticals?

Allan Hillgrove, Corporate Board Division, Pharma Marketing and Sales discusses the ongoing transformation of Boehringer Ingelheim’s portfolio.

Boehringer Ingelheim Upping Manufacturing Capacity

NewsBoehringer Ingelheim breaks ground on $217 million expansion of Fremont, California manufacturing facility. Expansion will triple capacity, add nearly 300 new jobs.

Boehringer Ingelheim and Sarah Cannon Research Institute to Investigate Novel Immuno-Oncology Combination Therapy

INGELHEIM, Germany & NASHVILLE, Tenn.–(BUSINESS WIRE)–Boehringer Ingelheim and Sarah Cannon Research Institute today announced an expansion of their strategic partnership to bring inno...

Drugs and Medications [1358 Associated Drugs and Medications listed on BioPortfolio]

Zantac [Boehringer Ingelheim Pharmaceuticals, Inc.]

Zantac Drug Facts

Zantac [Boehringer Ingelheim Pharmaceuticals, Inc.]

Zantac Drug Facts

Zantac [Boehringer Ingelheim Pharmaceuticals, Inc.]

Zantac Drug Facts

Dulcolax balance [Boehringer Ingelheim Pharmaceuticals Inc]

Boehringer-Ingelheim Consumer Health Care Products Dulcolax Balance® Drug Facts

Pradaxa [Boehringer Ingelheim Pharmaceuticals Inc.]

These highlights do not include all the information needed to use PRADAXA safely and effectively. See full prescribing information for PRADAXA. PRADAXA® (dabigatran etexilate mesylate) capsules for o...

PubMed Articles [30 Associated PubMed Articles listed on BioPortfolio]

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.

The interleukin-23 pathway is implicated genetically and biologically in the pathogenesis of Crohn's disease. We aimed to assess the efficacy and safety of risankizumab (BI 655066, Boehringer Ingelhei...

Editorial: In Good Company.

Sharing is Caring: The Case for Company-Level Collaboration in Pharmacoeconomic Modelling.

Evaluation of in-feed larch sawdust anti-inflammatory effect in sows.

The study aimed to investigate the possible anti-inflammatory activity of larch sawdust as feed supplement in lactating sows' diet and its possible effect on the prevalence of Postpartum Dysgalactia S...

What do company health insurance plans provide?

Company health insurance plans are a voluntary employer benefit and an increasingly important part of company pension and benefits systems. They enable employers to invest in the health of their emplo...

Clinical Trials [89 Associated Clinical Trials listed on BioPortfolio]

Relative Bioavailability Study Between Two Formulations Containing Ambroxol Hydrochloride

to evaluate the bioavailability of ambroxol hydrochloride soft pastilles (test formulation), manufactured by Bolder Arzneimittel GmbH & Co. KG to Boehringer Ingelheim compared to ambroxol ...

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Linagliptin from Prevaglip 5 mg tablets(Eva pharma for Pharmaceuticals & Me...

Bioequivalence Study of Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited Under Fed Condition

The objective of this study is to determine the relative bioavailability of one 15 mg Meloxicam tablet (Dr. Reddy. Laboratories Ltd.,Generics) versus one 15 mg Mobic (meloxicam) Tablet (Bo...

Bioequivalency Study of Meloxicam Tablets Under Fasting Conditions

The objective of this study was the bioequivalence of a Roxane Laboratories' Meloxicam tablets, 15 mg, to Mobic® Tablets, 15 mg (Boehringer Ingelheim) under fasting conditions using a sin...

Bioequivalence Study of Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited Under Fasting Condition

The objective of this study is to determine the relative bioavailability of one 15 mg Meloxicam tablet (Dr. Reddy. Laboratories Ltd.,Generics) versus one 15 mg Mobic (meloxicam) Tablet (Bo...

Companies [1506 Associated Companies listed on BioPortfolio]

Nippon Boehringer Ingelheim Company Limited

Diagnostics

Boehringer Ingelheim Limited

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146...

Boehringer Ingelheim Pharmaceuticals Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group ...

Boehringer Ingelheim Pharma GmbH & Co. KG

Boehringer Ingelheim erforscht, entwickelt, produziert und vermarktet Arzneimittel für Menschen in aller Welt.Mit 37.406 Mitarbeitern, die in 143 Gesellschaften auf allen Kontinenten beschäftigt sin...

Boehringer Ingelheim Pharmaceuticals, Inc.

Metabolism is one of Boehringer Ingelheim's core R&D areas and diabetes is one of the indications at the center of interest within the company's global research network. Boehringer Ingelheim is commit...

More Information about "Nippon Boehringer Ingelheim Company Limited" on BioPortfolio

We have published hundreds of Nippon Boehringer Ingelheim Company Limited news stories on BioPortfolio along with dozens of Nippon Boehringer Ingelheim Company Limited Clinical Trials and PubMed Articles about Nippon Boehringer Ingelheim Company Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Nippon Boehringer Ingelheim Company Limited Companies in our database. You can also find out about relevant Nippon Boehringer Ingelheim Company Limited Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record